Neurology. 2003 Aug 26;61(4):551-4
Tremlett HL, Oger J.
Division of Neurology, Department of Medicine, University of British Columbia, Vancouver Hospital and Health Sciences Center, Canada.
A retrospective chart review of patients in British Columbia with multiple sclerosis prescribed beta-interferon (IFNbeta) between 1995 and 2001 was carried out to investigate reasons for the interruption of therapy.
The highest proportion of interruptions (76/281; 27%) occurred in the first 6 months.
The single most common reason was perceived lack of efficacy, cited by 84 of 281 (30%).
Gender, disability, and disease duration were identified as factors influencing interruption of IFNbeta therapy.